Sign In
Buy ACRS
$4.92
+0.0800 (+1.65%)
At Close: Jun 23, 2026
3 Penny Stocks Under $5 Backed by Real Revenue Growth
05:35pm, Tuesday, 23'rd Jun 2026
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
3 Penny Stocks Under $5 Backed by Real Revenue Growth
09:20am, Saturday, 20'th Jun 2026
Investing in penny stocks requires significant conviction. Many of the companies in this group are purely “story stocks.
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
03:03pm, Thursday, 04'th Jun 2026
Aclaris Therapeutics NASDAQ: ACRS executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upc
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
08:30am, Thursday, 28'th May 2026
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammator
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
02:30pm, Thursday, 14'th May 2026
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08:30am, Friday, 08'th May 2026
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammator
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
09:51am, Thursday, 07'th May 2026
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
06:59am, Thursday, 07'th May 2026
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
02:01pm, Tuesday, 28'th Apr 2026
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
06:30am, Tuesday, 28'th Apr 2026
- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Ex
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
04:45pm, Monday, 27'th Apr 2026
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4%
01:09am, Tuesday, 14'th Apr 2026
Aclaris Therapeutics, Inc. (NASDAQ: ACRS - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,017,767 shares
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
08:30am, Wednesday, 08'th Apr 2026
WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEW
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammat
